P reeclampsia (PE) is a serious and common complication during pregnancy and remains a leading cause of maternal and neonatal morbidity and mortality. [1][2][3] It is a multisystem disorder generally appearing after the 20th week of gestation and characterized by hypertension, proteinuria, inflammation, and endothelial dysfunction. [4][5][6] Despite intensive research and large clinical trials, the underlying cause of PE remains a mystery and satisfactory treatment options are lacking.
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February 2013 vascular endothelial growth factor (VEGF 121 ) serves to neutralize excessive sFlt-1 and, thereby, significantly ameliorates both hypertension and proteinuria in autoantibody-infused pregnant mice, indicating sFlt-1 is a key mediator of AT 1 -AA-induced features of PE. 13 Supporting these animal studies, human studies indicate that AT 1 -AAs are highly associated with PE and their titers are proportional to disease severity. 14 Thus, both human and animal studies support a novel concept that circulating AT 1 -AA is a pathogenic biomarker contributing to PE.
During normal pregnancy there is a marked expansion in plasma volume and an increase in cardiac output that is associated with a major increase in the concentration of circulating aldosterone. Increased aldosterone levels presumably contribute to sodium retention and the resultant water retention associated with volume expansion during pregnancy. [15] [16] [17] However, in patients with PE there is an inadequate plasma volume expansion coupled with a suppressed level of aldosterone. 16, [18] [19] [20] [21] [22] Factors accounting for the reduction in aldosterone production associated with PE are not well understood. The goal of the current research was to address the puzzle of reduced aldosterone levels in women with PE relative to normotensive (NT) pregnant women. We present evidence that AT 1 -AA-mediated induction of sFlt-1 results in adrenal gland vascular impairment and decreased aldosterone production, features that can be prevented by infusion of VEGF 121.
Materials and Methods
An expanded Methods section is available in the online-only Data Supplement Methods.
Patient Samples
Patients admitted to Memorial Hermann Hospital were identified by the obstetrics faculty of the University of Texas Medical School at Houston. Preeclamptic patients were diagnosed with severe disease on the basis of the definition set by the National High Blood Pressure Education Program Working Group Report. NT pregnant women were selected on the basis of having an uncomplicated, NT pregnancy with a normal term delivery. Blood samples were collected shortly after diagnosis. The research protocol, including informed consent form, was approved by the Institutional Committee for the Protection of Human Subjects. The patient clinical data are listed in the Table. Body mass index is based on self-reported prepregnancy height and weight. Increased body mass index is a well-known risk factor for PE.
CD34 Immunohistochemistry and Quantification
Immunohistochemistry for CD34 was carried out on formalin fixed tissues as previously described. [23] [24] [25] [26] The histological quantification of CD34 was carried out using Image-Pro Plus software (Media Cybernetics, Bethesda, MD). Slides with CD34 staining were examined under ×100magnification. The microvessels that were examined for CD34 staining were mostly concentrated along the corticomedullary junction of the adrenal glands, and hence only those areas were closely examined for the CD34 staining.
Statistical Analysis
Results are expressed as mean±SEM. All data were subjected to statistical analysis using 1-way ANOVA followed by Newman Keuls post hoc test or Student t test to determine the significance between groups. Statistical programs were run by GraphPad Prism 5, statistical software (GraphPad, San Diego, CA). Statistical significance was set at P<0.05.
Results

Reduced Aldosterone Levels Are Associated With the Presence of AT 1 -AA and Elevated Circulating sFlt-1 Levels in the Serum of Pregnant Women With PE
We used a sensitive luciferase bioassay to detect AT 1 -AA, 14 ELISA for sFlt-1, and enzyme immunoassay for aldosterone to measure their circulating levels in NT pregnant women and those with PE. Consistent with earlier reports, 18 our current study showed significantly decreased serum aldosterone levels Reduced aldosterone levels in sera of women with preeclampsia (PE) are associated with the presence of angiotensin II type 1 receptor agonistic autoantibody (AT1-AA) and elevation of soluble Fms-like tyrosine kinase-1 (sFlt-1) levels. A, Aldosterone levels in the sera of normotensive (NT) pregnant women and women with PE were measured by enzyme immunoassay specific for aldosterone. Aldosterone levels were significantly reduced in PE sera compared with NT sera. B, AT 1 -AA levels in NT and PE sera were quantified by an nuclear factor of activated T cells-luciferase bioassay that reflects AT1 receptor activation. AT 1 -AA activity was significantly elevated in IgG prepared from PE compared with NT sera. C, sFlt-1 levels in NT and PE sera were measured by ELISA. sFlt-1 levels were significantly increased in PE compared with NT sera. *P<0.05 vs NT, n=12 for NT and 15 for PE. in PE patients (3602±514 pg/mL) compared with NT women (5176±417 pg/mL; P<0.05; Figure 1A ). In contrast, AT 1 -AA activity and sFlt-1 levels in the sera of women with PE were significantly increased (P<0.05; Figure 1B and 1C). Thus, these studies indicate that the presence of AT 1 -AA and elevated sFlt-1 levels in the circulation of preeclamptic women are associated with reduced circulating adolsterone levels.
IgG Isolated From Women With PE Leads to Decreased Aldosterone Production in Pregnant Mice and Increased Aldosterone Production in Nonpregnant Mice
We used an antibody-injection model of PE in pregnant mice to determine whether aldosterone levels are decreased in this model. Blood pressure and proteinuria significantly increased in pregnant mice injected with IgG from women with PE (PE-IgG) compared with pregnant mice injected with IgG from NT pregnant women (NT-IgG) (142±8 versus 124±2 mm Hg; 242±27 versus 132±17 µg albumin/mg creatinine both P<0.05; Figure 2A and 2B). Coinjection with losartan (an AT 1 R antagonist) or a 7-aa epitope peptide that inhibits autoantibody-induced AT 1 receptor activation prevented autoantibody-induced hypertension and proteinuria ( Figure  2A and 2B). These findings demonstrate that the autoantibody-induced hypertension and proteinuria in pregnant mice resulted from AT 1 receptor activation. Next, we extended our studies to determine aldosterone levels in the autoantibody-induced preeclamptic mouse model. Aldosterone levels were significantly decreased in the serum of mice injected with PE-IgG (544±92 pg/mL) compared with pregnant mice injected with NT-IgG (1377±272 pg/mL; P<0.01; Figure 3A ). To determine whether reduced aldosterone levels were dependent on autoantibody-mediated AT 1 R activation, we coinjected the pregnant mice with PE-IgG and the 7-aa epitope peptide. 9, 11 We found ( Figure 3A ) that coinjection with the 7-aa epitope peptide blunted the reduction in aldosterone levels (1192±318 pg/mL; P<0.05) resulting from injection of PE-IgG. This study provides the first in vivo evidence that IgG circulating in preeclamptic women is a causative factor contributing to reduced aldosterone levels via AT 1 R activation in pregnant mice. In contrast to the reduction in aldosterone levels we observed in pregnant mice, the injection of PE-IgG into nonpregnant mice resulted in an increase in aldosterone production and its elevation was significantly attenuated by On gestational day 18, aldosterone levels in the serum of PE-IgG-injected pregnant mice were significantly reduced compared with NT-IgG-injected pregnant mice. The 7-aa epitope peptide coinjection attenuated the reduced aldosterone production in PE-IgG-injected mice. *P<0.05 compared with NT, **P<0.05 compared with PE (n=5-7 injected mice per experimental group). B, PE-IgG but not NT-IgG significantly induced circulating adosterone concentration in nonpregnant mice. Nonpregnant mice were injected with NT-IgG or PEIgG on 2 consecutive days. Five days after the first injection, aldosterone levels in the serum of PE-IgG-injected nonpregnant mice were significantly induced compared with NT-IgG-injected nonpregnant mice. The 7-aa epitope peptide coinjection reduced the elevated aldosterone production in PE-IgG-injected mice *P<0.05 compared with NT, **P<0.05 compared with PE (n=6-8 injected mice per experimental group). coinjection of the 7-aa epitope peptide ( Figure 3B ), indicating that AT 1 -AA is capable of inducing aldosterone production in nonpregnant mice via AT 1 R activation. Taken together, these results demonstrate that the detrimental effects of PE-IgG on aldosterone production are specific for pregnancy.
Adrenal Gland Vascular Impairment in PE-IgG-Injected Pregnant Mice
In an effort to determine the basis for reduced aldosterone production in PE-IgG-injected pregnant mice we isolated adrenal glands from these mice and conducted histological analysis. We observed that the outermost zone of the cortex of adrenal glands, the zona glomerulosa, which is exclusively responsible for aldosterone production, displayed a highly disorganized pattern in the arrangement of the cellular components, including nonuniform arrangement of the nuclei because of disruption in cellular morphology ( Figure 4A and 4B). These abnormalities were not observed in the adrenal gland sections in the NT-IgG-injected pregnant mice or mice treated with the 7-aa epitope peptide ( Figure 4A and 4B), indicating that PE-IgG-induced disorganization and cellular injury of the zona glomerulosa layer is mediated by AT 1 R activation. Under higher magnification, a closer examination of the corticomedullary junction revealed the rich vasculature of the adrenal glands. The region was characterized by branching and spreading of the cortical capillaries in the cortex area of the NT-IgG-injected pregnant mice. The presence of the cortical capillaries was diminished and had less branching in the PE-IgG-injected mice, compared with the NT-IgG-injected mice ( Figure 4C ). Significantly, coinjection of the PE-IgG pregnant mice with the 7-aa epitope peptide ameliorated the features seen in the PE-IgG-injected mice, resulting in increased presence and branching of the cortical capillaries ( Figure 4C ), demonstrating that PE-IgG leads to vascular impairment in adrenal glands, a feature that was not observed in the NT-IgG-injected mice and was prevented by the administration of the 7-aa epitope peptide. Finally, to accurately measure the effects of PE-IgG on adrenal gland vascularity in pregnant mice, we examined the expression of the CD34 as a vascular marker in the adrenal glands of the mice from all groups. CD34 staining has been used to report the microvasculature density in the adrenal glands. [23] [24] [25] [26] Following this approach we detected CD34 in the endothelium of the blood vessels (microvessels) in the sinusoidal areas mostly in the corticomedullary junction of the adrenal glands ( Figure 5A ). Close examination at higher magnification revealed that those microvessels, extending deep into the cortex, were present in abundance in NT-IgG-injected pregnant mice. However, the microvessels stained with CD34 in these areas displayed substantial reduction in size and branching into the cortex in PE-IgGinjected pregnant mice ( Figure 5A ). Of note, the impaired vasculature seen in the adrenal gland of PE-injected pregnant mice was ameliorated by coinjection with the 7-aa epitope peptide ( Figure 5A ). Quantitative image analysis of CD34 immunostaining demonstrated significantly less immunoreactivity in adrenal gland sections from mice injected with PE-IgG compared with those from mice injected with NT-IgG or in mice coinjected with PE-IgG and the 7-aa epitope peptide ( Figure 5B ). Overall, these results indicate that the introduction of PE-IgG into pregnant mice results in adrenal gland vascular impairment.
VEGF 121 Treatment Prevents Adrenal Vascular Impairment and Improves Aldosterone Production in Adrenal Glands of Autoantibody-Injected Mice
Circulating levels of sFlt-1 are elevated in women with PE and in pregnant mice injected with PE-IgG ( Figure 6A ). PE IgGinduced production of sFlt-1 is inhibited by coinjection with Figure 4 . Autoantibody-induced cellular and vascular impairment in adrenal glands of pregnant mice can be prevented by 7-aa epitope peptide and vascular endothelial growth factor (VEGF 121 ). A, Histological analysis of adrenal glands, assessed by hematoxylin and eosin (H&E) staining, indicated that the arrangement of the cellular components within the zona glomerulosa (ZG) layer of the adrenal glands displayed a disorganized and nonuniform pattern in the preeclampsia (PE)-IgG group compared with normotensive (NT)-IgG group (×20, scale bar, 50 µm). B, The cellular components, including nuclei, were found to be irregularly placed in patches, shrunken, and clustered in PE-IgG-injected mice (×100, scale bar, 10 µm). C, H&E staining showed that the corticomedullary junction area (CA) of the adrenal glands of PE-IgG-injected pregnant mice displayed substantially diminished capillaries with less branching compared with the NT-IgG-injected mice (×100, scale bar, 10 µm; n=5-7). C indicates cortex; M, medulla; and S, sinusoid.
by guest on June 2, 2017 http://hyper.ahajournals.org/ Downloaded from the 7-aa epitope peptide that blocks autoantibody-mediated AT 1 R activation. sFlt-1 is a potent antagonist of VEGF signaling with detrimental effects on endothelial cells. Thus, it is possible that the antiangiogenic properties of excessive sFlt-1 produced in the antibody-injection model of PE in pregnant mice is responsible for the reduced aldosterone observed in this model. To test this possibility, we infused VEGF 121 into PE-IgG-injected pregnant mice to neutralize excessive sFlt-1 and potentially prevent autoantibody-mediated reduction in aldosterone. 13, 27 Consistent with our earlier studies, 13 we found that VEGF 121 infusion attenuated autoantibody-induced hypertension ( Figure 6B ). We also found that infusion of VEGF 121 significantly attenuated PE-IgG-induced adrenal damage and impaired vascularity in pregnant mice ( Figure 5A and 5B). Of significance, VEGF 121 treatment of PE-IgG-injected pregnant mice resulted in substantially increased aldosterone levels (1110±269 pg/mL) compared with those in the mice injected with PE-IgG alone (544±92 pg/mL) ( Figure 6C ). These findings suggest that AT 1 -AA-mediated sFlt-1 elevation underlies reduced aldosterone production by promoting adrenal gland vascular damage in the pregnant mice.
Discussion
Normal human pregnancy, compared with nonpregnant state, is characterized by elevated aldosterone levels in the circulation. 15, 16 In contrast, pregnancies complicated by PE are associated with reduced levels of aldosterone, compared with NT pregnancies. 19, 20 The causative factors responsible for reduced aldosterone production in PE are unidentified. In this study, we have provided evidence that reduced aldosterone levels are associated with the presence of circulating AT 1 -AA and elevated sFlt-1 levels in the sera of preeclamptic women. Using an adoptive transfer animal model of PE, we show that the injection of IgG from women with PE, in contrast to IgG from NT pregnant women, results in hypertension, proteinuria, and a reduction in aldosterone production. These features were prevented when mice were coinjected with an antibody blocking 7-aa epitope peptide, indicating that these features, including the reduction in aldosterone levels, resulted from antibody-mediated AT 1 receptor activation. Significantly, these features were also mitigated by infusion of VEGF 121 to neutralize the effects of excessive sFlt-1. Overall, our findings support a model in which AT 1 -AA in preeclamptic women is a pathogenic factor responsible for reduced aldosterone levels.
Because AT 1 -AA acts like a functional mimic of angiotensin II (Ang II), and Ang II is known to stimulate aldosterone release from the adrenal glands, one would expect that the introduction of AT 1 -AA into mice would result in increased production of aldosterone. Based on this expectation we were not surprised to see that AT 1 -AA stimulated aldosterone production when injected into nonpregnant mice. However, the introduction of AT 1 -AA into pregnant mice resulted in reduced aldosterone levels, a feature associated with PE as shown here by us and previously by others. 10 Evidence provided here suggests that elevated sFlt-1in PE may contribute to adrenal gland vascular impairment and reduced aldosterone production. Normal pregnancy leads to an increase in sFlt-1 production compared with the nonpregnant state. However, sFlt-1 levels are further increased in PE compared with NT pregnancy. Our earlier studies showed that AT 1 -AA-mediated activation of AT 1 Rs contributes to elevated sFlt-1 production from the placenta in a mouse model of PE. 16, 20 Thus, it is possible that the AT 1 -AA-mediated increase in circulating sFlt-1 is a pregnancy-specific factor responsible for reduced aldosterone production. Supporting this possibility, we report here that the adrenal glands of autoantibody-injected pregnant mice display vascular impairment, associated with reduced aldosterone production. Second, we provide in vivo evidence that neutralizing elevated sFlt-1 by infusion of VEGF 121 resulted in improved adrenal gland vascularity associated with increased aldosterone production. Thus, our studies suggest a role for AT 1 -AA in adrenal gland vascular impairment and subsequent reduction of aldosterone production in PE-IgGinjected pregnant mice. It is noteworthy that PE-IgG induces sFlt-1 production only in pregnant mice, not nonpregnant mice. Thus, in the absence of sFlt-1 induction in nonpregnant mice, PE-IgG injection did not result in adrenal gland vascular impairment, but rather mediated an increase in aldosterone production via AT 1 R activation. Overall our findings support the hypothesis that autoantibody-mediated induction of Figure 5. Antibody-induced vascular impairment in adrenal glands of the pregnant mouse was attenuated by 7-aa epitope peptide or vascular endothelial growth factor (VEGF 121 ). Adrenal gland vascularity was assessed by CD34 immunostaining. A, CD34 immunostaining showed that CD34 was specifically expressed in the endothelium of the blood vessels (microvessels, MV) in the sinusoidal areas (S) between the cortex and medulla (M). (×100, scale bar, 10 µm). Microscopic examination revealed the presence of microvessels at the corticomedullary junction of the adrenal glands. The incidence of microvessels in large areas that branched deeply into the cortex was evident by the CD34 staining in the normotensive (NT)-IgG-injected mice. CD34 staining was decreased in the preeclampsia (PE)-IgGinjected pregnant mice and 7-aa epitope peptide coinjection or VEGF 121 infusion attenuated vascular impairment in these mice. B, An arbitrary histological quantification of CD34 staining. *P<0.05 compared with NT, **P<0.05 compared with PE.
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http://hyper.ahajournals.org/ Downloaded from sFlt-1 is a novel pathogenic mechanism promoting adrenal gland vascular impairment leading to decreased aldosterone production in pregnant mice and that the decline in aldosterone levels and adrenal gland vascular impairment can be prevented by infusion of VEGF 121 ( Figure 6D ). In a normal pregnancy the zona glomerulosa of the maternal adrenal gland remains responsive to the agonistic action of Ang II and aldosterone secretion increases as Ang II levels rise during pregnancy. 15, 19 However, the maternal vasculature is somewhat unresponsive to the pressor effects of Ang II, a feature consistent with the initial drop in blood pressure early in pregnancy. 28, 29 These 2 phenomena work together (ie, decreased Ang II pressor response and increased aldosterone production) to achieve an expansion of blood volume during pregnancy while maintaining control of blood pressure. In contrast, an increased responsiveness to the pressor effects of Ang II and a decrease in the production of aldosterone are observed in PE. These changes are associated with increased blood pressure and decreased plasma volume. 20, 21 Similar to preeclamptic women, we found that aldosterone production is reduced, whereas blood pressure is increased in autoantibody-injected pregnant mice. As explained in the following paragraph we believe that the inhibitory effect of PE-IgG injection on aldosterone production is because of antiangiogenic effects of excessive sFlt-1 produced by the placentas of pregnant mice.
It is well-known that VEGF is produced by steroidogenic cells of the adrenal cortex and that VEGF receptors are present on adreno-cortical capillary endothelial cells. [30] [31] [32] Earlier studies have shown that VEGF exerts paracrine control over the vasculature of the adult adrenal cortex where it plays a critical role in maintaining the dense and fenestrated vascular bed of the adrenal cortex. 33 We believe that the disruption of paracrine VEGF signaling in the adrenal cortex by excessive concentrations of the VEGF antagonist, sFlt-1, is detrimental to adrenal vascular homeostasis. This view is supported by our data showing that the detrimental effects of AT 1 -AA on adrenal-cortical vasculature and aldosterone production Figure 6 . Vascular endothelial growth factor (VEGF 121 ) infusion prevented the preeclampsia (PE)-IgG-induced hypertension and reduction of aldosterone production in pregnant mice. A, Soluble Fms-like tyrosine kinase-1 (sFlt-1) levels in the serum were significantly increased in pregnant mice compared with nonpregnant mice and further induced in the PE-IgG-injected pregnant mice (PE) compared with normotensive (NT)-IgG-injected pregnant mice (NT). The 7-aa epitope peptide coinjection (PE+7aa) attenuated PE-IgG-mediated sFlt-1 induction in the serum of pregnant mice. *P<0.05 compared with nonpregnant mice, **P<0.05 compared with NT. ***P<0.05 compared with PE (n=6 or 7 injected mice per experimental group). B, VEGF 121 infusion significantly attenuated PE-IgG-induced hypertension in pregnant mice. Pregnant mice were injected with either PE-IgG or NT-IgG on gestation days 13.5 and 14.5. Some of the PE-IgG-injected mice were continuously infused with VEGF 121 . Blood pressure was determined immediately before the initial injection and at 3 and 5 days after the initial injection. *P<0.05 compared with NT, **P<0.05 compared with PE (n=5 or 6 mice per experimental group). C, Aldosterone levels in the serum of PE-IgG-injected pregnant mice were significantly reduced compared with NT-IgG-injected pregnant mice. VEGF 121 infusion attenuated the reduction in aldosterone production in PE-IgG-injected mice *P<0.05 compared with NT, **P<0.05 compared with PE (n=5-7 injected mice per experimental group). D, Working model of angiotensin II type 1 receptor agonistic autoantibody (AT 1 -AA) in PE. Our findings suggest that AT 1 -AA contributes to reduced aldosterone production via elevated sFlt-1 production which contributes to adrenal gland vascular impairment and reduced aldosterone production. AT 1 -AA-mediated induction of sFlt-1 and the resulting inhibition of VEGF signaling also has detrimental effects on renal and vascular function leading to proteinuria and hypertension. Overall, AT 1 -AA is a detrimental factor contributing to multiple features associated with PE in a sFlt-1-dependent manner that is based on interference with VEGF signaling. Thus, interfering with AT 1 -AA-mediated angiotensin type 1 receptor (AT 1 R) receptor activation or neutralizing the effects of increased sFlt-1 by the infusion of VEGF 121 represent important therapeutic possibilities for PE. by guest on June 2, 2017 http://hyper.ahajournals.org/ Downloaded from are corrected by infusion of VEGF 121 , to overcome the inhibitory effects of sFlt-1. We do not believe that the activation of adrenal AT 1 receptors by AT 1 -AA is directly responsible for adrenal gland impairment and reduced aldosterone production in pregnant mice. Instead we propose that the autoantibodyinduced production of excessive sFlt-1 by the placentas of pregnant mice results in the disruption of paracrine VEGF signaling required for adrenal vascular homeostasis.
Earlier studies have demonstrated detrimental effects of excessive sFlt-1 on kidneys, resulting in glomerular endotheliosis and renal dysfunction, manifested as proteinuria. 34, 35 Previous studies from our laboratory have shown that AT 1 -AAmediated kidney injury in pregnant mice is dependent on antibody-induced sFlt-1 production because VEGF 121 infusion significantly reduced autoantibody-induced proteinuria and kidney injury. 13 We show here that AT 1 -AA-mediated sFlt-1 induction also contributes to impaired adrenal vasculature and decreased aldosterone production in pregnant mice, features that are reversed by administration of VEGF 121 . Taken together, our current studies support a novel working model in which AT1-AA-mediated kidney and adrenal gland dysfunction in pregnant mice is dependent on the antiangiogenic consequences of excessive placenta-derived sFlt-1. The use of VEGF 121 to overcome the detrimental effects of excessive sFlt-1 has significant therapeutic potential.
Perspectives
Here we report that maternal circulating AT 1 -AA levels are associated with elevated sFlt-1 and reduced aldosterone levels in the sera of preeclamptic women. In vivo adoptive transfer studies led to unexpected findings that AT 1 -AA contributes to the reduction of aldosterone production as seen in preeclamptic women. Intriguingly, we further discovered that AT 1 -AAmediated reduction of aldosterone is associated with adrenal gland vascular impairment, a feature attributed to AT 1 -AAmediated sFlt-1 induction. Significantly, infusion of VEGF 121 to neutralize elevated sFlt-1 production prevented AT 1 -AAinduced hypertension and adrenal vascular impairment and resulted in the recovery of aldosterone production in pregnant mice. Overall, our findings reveal novel factors and signaling cascades involved in decreased aldosterone production in PE and highlight possible therapeutic interventions in the management of PE.
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